← FDA DRUG APPROVALS

FDA ANDA · ANDA062746

ERYTHROMYCIN

Sponsor: CARNEGIE

APPLICATION
ANDA062746
TYPE
ANDA
ORIGINAL APPROVAL
1986-12-22
LATEST ACTION
2022-03-10
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription

Products

ERYTHROMYCINPrescription
ERYTHROMYCIN 250MG · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2022-03-10Labeling · Supplement 14 · standardAP
2022-03-10Labeling · Supplement 12 · standardAP
2009-09-28Labeling · Supplement 10AP
2009-07-06Labeling · Supplement 9AP
2004-03-17Labeling · Supplement 5AP
1998-04-20Manufacturing (CMC) · Supplement 6AP
1986-12-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →